NGNE

Neurogene

• TipRanks·5d ago

  Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway

• TipRanks·05/16 14:36

  LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)

• TipRanks·05/15 13:42

  Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY)

• TipRanks·05/13 13:05

  Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target

• TipRanks·05/13 13:00

  Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)

• TipRanks·05/13 12:20

  Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)

• TipRanks·05/13 12:00

  Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Neurogene (NGNE) and Stereotaxis (STXS)

• TipRanks·05/13 11:48

  Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)

• TipRanks·05/12 21:23

  Neurogene reports Q1 EPS ($1.39), consensus ($1.27)

• Benzinga·05/12 21:06

  Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate

• Seeking Alpha·05/12 20:43

  Neurogene GAAP EPS of -$1.39 misses by $0.09

• PUBT·05/12 20:41

  Neurogene posts corporate deck highlighting NGN-401 gene therapy program for Rett syndrome

• Reuters·05/12 20:13

  Neurogene Q1 net loss widens on higher R&D costs

• Dow Jones·05/12 20:11

  *Neurogene 1Q Loss $30.9M >NGNE

• Dow Jones·05/12 20:05

  Press Release: Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates